SNES - Dividend announcements

Intended to Facilitate a Reverse Stock Split, if Necessary PHOENIX, Aug. 26, 2022 /PRNewswire/ -- SenesTech, Inc.  (NASDAQ:SNES, ", SenesTech", or the ", Company", ))) (www.senestech.com), the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.001 per share, for each outstanding share of SenesTech common stock held of record on September 5, 2022.  The outstanding shares of Series C Preferred Stock will vote together with the outstanding shares of the Company's com

PHOENIX, May 13, 2021 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), (www.senestech.com) the rodent fertility control experts and inventors of the first and only registered rat contraceptive, ContraPest® announced today revenues for the first quarter in 2021 were up 138 percent from the same period a year ago while operating expenses have been reduced by 20 percent. During the past year, SenesTech has transitioned from a science-based research company to a solutions-based, environmentally responsible commercial company providing a new and proven tool to pest control management for the 21st century. After more than five years of successful testing and deployment in municipal, agricultural, co

PHOENIX, March 25, 2021 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary, next generation technologies for managing animal pest populations through fertility control, today announced financial and operational results for the fourth quarter and fiscal year 2020, which ended on December 31, 2020. Ken Siegel, CEO of SenesTech, commented, "We made significant progress in 2020 in building awareness and adoption of ContraPest, as evidenced by a 97% year-over-year increase in revenue. Although the revenue increase is from a relatively small base, we are making measurable progress despite the continuing pandemic. Importantly, we recently concluded pivotal ContraPest monitor